William S. Richmond
Overview
Will Richmond is a corporate healthcare partner in the Washington, D.C., office of Kirkland & Ellis LLP, with significant experience advising clients on life science and healthcare regulatory transactions and compliance. Will counsels private equity funds, venture capital firms, and public and private companies on a broad range of regulatory and transactional matters, with a particular focus on drug manufacturers, contract development and manufacturing organizations (CDMOs), clinical trial operators, healthcare providers, managed care organizations, management and dental support organizations, and nonprofit hospital systems. Will has broad experience with federal and state laws/regulations as well as contractual considerations that impact healthcare entities.
Will regularly guides clients through the complex regulatory frameworks enforced by the U.S. Food and Drug Administration (FDA), including issues related to drug and biologic development, manufacturing compliance, inspections and enforcement actions. He also advises on a wide range of healthcare regulatory matters such as healthcare fraud and abuse laws (Anti-Kickback Statute, Stark Law), HIPAA compliance, corporate practice of medicine restrictions, reimbursement and commercial contracting.
Will’s transactional experience includes term sheet negotiations, deal structuring, diligence, regulatory filings, representation and warranty insurance (RWI), and lender negotiations. He frequently assists clients with regulatory audits and inspections, investigations, compliance program development, and the application of state healthcare transaction and change-of-ownership laws.
Will is also experienced in advising clients on healthcare regulatory issues in the context of restructurings, bankruptcies and liability management transactions.
Experience
Representative Matters
Life Sciences
- BayPine in its acquisition of CenExel Clinical Research, a provider of a clinical trial site network
- Olympus Partners in its acquisition of PAI Pharma
- Owens & Minor (NYSE: OMI) in its pending $1.36 billion acquisition of Rotech Healthcare, a provider of home medical equipment
- Avista Healthcare Partners in its acquisition of Trillium Health Care Products, a contract development and manufacturing organization of branded over-the-counter products, from New Water Capital
- Trilantic North America in its investment in SOFIE Biosciences, a Positron Emission Tomography (PET) radiopharmacy and contract development and manufacturing organization (CDMO)
- Silver Oak backed-Integrated Oncology Network, a provider of oncology services, in its pending $1.115 billion sale to Cardinal Health (NYSE: CAH)
- EQT-led consortium in the £4.5 billion acquisition of Dechra Pharmaceuticals (LSE: DPH), a provider of specialist veterinary pharmaceuticals and related products
- Nordic Capital in its acquisition of IntegriChain, a platform for pharma commercialization and market access, from Accel-KKR
- Bristol Myers Squibb (NYSE: BMY) in its $5.8 billion acquisition of Mirati Therapeutics (NASDAQ: MRTX), a commercial stage research and development biotechnology company
- Owens & Minor (NYSE: OMI) in its $1.6 billion acquisition of Apria (NASDAQ: APR), a provider of integrated home healthcare equipment and related services
- EQT-backed Recipharm in its acquisition of Arranta Bio, an advanced therapy medicinal products (ATMPs) contract development and manufacturing organization (CDMO), from Ampersand Capital Partners
- EQT-backed Recipharm in its acquisition of Vibalogics, a virotherapy contract development and manufacturing organization (CDMO), from Ampersand Capital Partners
- The Jordan Company in its investment in WEP Clinical, a specialist pharma services company that works with drug developers to help patients and physicians gain early access to medicines
Healthcare Providers
- Brookfield in its $185 million strategic investment into Orthopedic Care Partners
- Silver Oak backed-Integrated Oncology Network, a provider of oncology services, in its $1.115 billion sale to Cardinal Health (NYSE: CAH)
- VSP Vision in its acquisition of Eyemart Express from FFL Partners and Leonard Green & Partners
- Cressey & Company in the acquisition of HealthDrive, a provider of clinical services to patients residing in long-term care facilities, from Bain Capital Double Impact
- TPG's The Rise Fund in its investment in Banyan Treatment Centers, a provider of substance use disorder and mental health services
- Vertava Health of Mississippi, a provider of addiction treatment and mental health services, in its sale to Bradford Health Services
- Percheron Capital-backed Animal Dermatology Group in its acquisition of Animal Dermatology and Allergy Specialists
- Seattle Reproductive Medicine, a fertility center, in its sale to Pinnacle Fertility
Healthcare Technology
- Bain Capital Tech Opportunities in its investment in the combination of Greenphire, a provider of clinical trial payments, financial management and patient support tools, and Suvoda, a clinical trial technology company
- Trinity Hunt Partners in its investment in TNT Dental, a digital marketing agency
- GTCR, alongside Avryo Health Services, in its investment in 7to7 Dental, a dental service organization
- Trinity Hunt Partners in its investment in Coker, a healthcare advisory firm
- GTCR-backed RevSpring, a provider of communication and payment solutions, in its sale to Frazier Healthcare Partners
- Olympus Partners in the sale of Soliant, a provider of workforce solutions in K-12 school districts and healthcare facilities, to The Vistria Group
- Stone Point Capital-backed Tivity Health in its acquisition of Burnalong, a digital health, wellness and fitness platform
- EW Healthcare Partners in its acquisition of Enercon Technologies, a provider of electronic product development and manufacturing services
- Vesey Street Capital Partners in its sale of QualityMetric, a provider of tools and technology that measure health from the patient's point of view
- Olympus Partners in its acquisition of EyeSouth Partners, an eye care management services organization, from Shore Capital Partners
- Francisco Partners in its acquisition of the healthcare data and analytics assets from IBM (NYSE: IBM) that are currently part of the Watson Health business
- Thoma Bravo in its $6.9 billion acquisition of SailPoint Technologies (NYSE: SAIL), enterprise identity security provider
- Bain Capital Private Equity in its investment in CitiusTech, a provider of technology and consulting services to healthcare and life sciences companies
Restructuring
- Invitae Corporation and certain of its affiliates in their prearranged Chapter 11 cases in the U.S. Bankruptcy Court for the District of New Jersey. Invitae is headquartered in San Francisco, California and is a leader in the genetic testing field. Prior to commencing Chapter 11, Invitae secured support to implement a go-forward sale process by signing a transaction support agreement with a significant majority of its secured noteholders
- Eyecare Service Partners in its $563 million recapitalization
Prior Experience
Nelson Mullins Riley & Scarborough
Ernst & Young
Pro Bono
More
Thought Leadership
Publications
Co-Author, “The Evolving Landscape of State Health Care Transaction Review Laws,” The American Health Law Association, Top Ten Issues in Health Law 2025
Credentials
Admissions & Qualifications
- District of Columbia
- New York
Education
- American University School of International ServiceM.A., International Affairs2020
- New York University School of LawLL.M., Taxation2018
- American University Washington College of LawJ.D.cum laude2017Editor-in-Chief, National Security Law Brief
- Clemson UniversityB.A., Political Science2014